Herbreteau, G.; Vallée, A.; Knol, A.-C.; Théoleyre, S.; Quéreux, G.; Varey, E.; Khammari, A.; Dréno, B.; Denis, M.G.
Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study. Cancers 2021, 13, 1826.
https://doi.org/10.3390/cancers13081826
AMA Style
Herbreteau G, Vallée A, Knol A-C, Théoleyre S, Quéreux G, Varey E, Khammari A, Dréno B, Denis MG.
Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study. Cancers. 2021; 13(8):1826.
https://doi.org/10.3390/cancers13081826
Chicago/Turabian Style
Herbreteau, Guillaume, Audrey Vallée, Anne-Chantal Knol, Sandrine Théoleyre, Gaëlle Quéreux, Emilie Varey, Amir Khammari, Brigitte Dréno, and Marc G. Denis.
2021. "Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study" Cancers 13, no. 8: 1826.
https://doi.org/10.3390/cancers13081826
APA Style
Herbreteau, G., Vallée, A., Knol, A.-C., Théoleyre, S., Quéreux, G., Varey, E., Khammari, A., Dréno, B., & Denis, M. G.
(2021). Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study. Cancers, 13(8), 1826.
https://doi.org/10.3390/cancers13081826